Trial of ceftazidime efficacy in respiratory infections at two dose levels.
A dose-ranging clinical trial of ceftazidime was carried out in patients with respiratory infections. Patients were randomly allocated to receive either 500 mg or 1 g doses of ceftazidime twice-daily intravenously. The organisms isolated from sputum were eradicated in 23 cases, and in 18 cases within 3 days. Five bacteriological failures were found during ceftazidime treatment (2 cases were not assessable), but only 2 of these patients had not clinically improved. There was no significant difference between the two dose regimes. The only adverse reaction was an allergic rash, occurring on the third day of treatment. This rash subsided rapidly on withdrawal of ceftazidime.